Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Trastuzumab With or Without Endocrine Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must be female.~* Signed informed consent.~* Locally advanced breast cancers or primary breast cancers are eligible. Locally advanced cancers must be of clinical and/or radiologic size \>3 cm, or \>2 cm with clinical evidence of axillary nodal involvement. (If tumors are less than 3 cm, we will use radiologically measured tumor size to determine the minimal tumor size for eligibility and in assessing tumor size during follow-up).~* HER2 overexpressing tumors defined as HercepTest score of 3+, or \> 10% cells moderately or strongly HER2 positive by other methods, or Allred semi-quantitative score of \>5, or gene amplified.~* Negative serum pregnancy test (HCG) within 7 days of starting study, if of child-bearing potential.~* Kidney and liver function tests - all within 1.5 times the institution's upper limit of normal.~* Performance status (WHO scale) less than 2 and life expectancy more than 6 months.~* Age at least 18 years.~* No brain or leptomeningeal disease.~* No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.~Note: The presence of pathological involvement of axillary nodes will be assessed and agreed upon by two investigators.~Exclusion Criteria:~* Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.~* Severe underlying chronic illness or disease.~* Cardiomyopathy or baseline LVEF less than 50%.~* Other investigational drugs while on study.~* Severe or uncontrolled hypertension, history of congestive heart failure or severe coronary arterial disease.~* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded~* Taking any lapatinib-prohibited medication within 7 days of first dose of study medications. (See Prohibited Medications List in protocol.)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Group Assignment (Type: EXPERIMENTAL): Lapatinib Trastuzumab Endocrine

Based on this trial design, predict the completion outcome and termination type (if applicable).